ANTI-C5 AGENT FOR TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATION (AMD) OR GEOGRAPHIC ATROPHY SECONDARY TO DRY AMD
This invention relates to methods and compositions useful for treatment of subjects with dry age-related macular degeneration or geographic atrophy secondary to dry age-related macular degeneration. The methods involve administration of a pharmaceutical composition comprising an anti-C5 agent ARC1905, which comprises a C5-specific aptamer conjugated to a polyethylene glycol moeity via a linker, in an amount effective for slowing or inhibiting loss of low luminance visual acuity in the subject. The aptamer consists of the sequence fCmGfCfCGfCmGmGfUfCfUfCmAmGmGfCGfCfUmGmAmGfUfCfUmGmAmGfUfUfUAfCf CfUmGfCmG-3T, wherein fC and fU=2′ fluoro nucleotides, mG and mA=2′-OMe nucleotides, all other nucleotides are 2′-OH, and 3T indicates an inverted deoxythymidine. Dosages and administration schedules are disclosed.
1 - 16 . (canceled)
17 . A method of treating geographic atrophy secondary to age-related macular degeneration in a human subject, the method comprising administering to said subject monthly, by intravitreal injection, an anti-C5 agent at a dose of 2 mg/eye,
wherein the anti-C5 agent comprises a C5-specific aptamer comprising the following structure:
or a salt thereof;
wherein Aptamer =
fCmGfCfCGfCmGmGfUfCfUfCmAmGmGfCGfCfUmGmAmGfUfCfU
mGmAmGfUfUfUAfCfCfUmGfCmG- - 3T (SEQ ID NO: 1),
wherein fC and fU=2′-fluoro nucleotides, mG and mA=2′-OMe nucleotides, all other nucleotides are 2′-OH, and 3T indicates an inverted deoxythymidine; and
wherein the method slows or inhibits loss of visual acuity in the human subject.
18 . The method of claim 17 , wherein administering the dose of 2 mg/eye of the anti-C5 agent comprises administering 0.1 mL of an aqueous solution via intravitreal injection, the aqueous solution containing the anti-C5 agent at a concentration of 20 mg/mL.
19 . The method of claim 18 , wherein the pegylated aptamer is administered in an aqueous solution further comprising one or more pH buffering agents and at least one tonicity adjuster.
20 . The method of claim 19 , where the one or more pH buffering agents comprise dibasic sodium phosphate heptahydrate and monobasic sodium phosphate monohydrate, and the at least one tonicity adjuster comprises sodium chloride.
21 . The method according to claim 17 , wherein the administration of the anti-C5 agent to the subject slows or inhibits the decrease in best corrected visual acuity as compared to a subject who is not administered the anti-C5 agent.
22 . The method according to claim 17 , wherein the administration of the anti-C5 agent to the subject increases the best corrected visual acuity as compared to a subject who is not administered the anti-C5 agent.
23 . The method according to claim 22 , wherein the increase is measured between baseline and at least or about 1 month.
24 . The method according to claim 22 , wherein the increase is measured between baseline and at least or about 6 months.
25 . The method according to claim 22 , wherein the increase is measured between baseline and at least or about 8 months.
26 . The method according to claim 22 , wherein the increase is measured between baseline and at least or about 12 months.
27 . The method according to claim 22 , wherein the increase is measured between baseline and at least or about 18 months.
28 . The method according to claim 22 , wherein the increase is measured between baseline and at least or about 24 months.
29 . The method according to claim 17 , wherein the best corrected visual acuity is measured using ETDRS letters.